Pharmacological chaperones in the age of proteomic pathology

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 34, 2014, Pages 12274-12275

  Small, Scott A ^a  

^a Departments of Neurology Radiology and Psychiatry Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; PROTEIN MCL 1; MYELOID LEUKEMIA FACTOR 1;

ALPHA HELIX; ALZHEIMER DISEASE; BINDING SITE; GENE EXPRESSION; GENE THERAPY; HIGH THROUGHPUT SCREENING; HUMAN; LYSOSOME; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DATABASE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; DRUG DEVELOPMENT; NEOPLASM;

ALPHA-SYNUCLEIN; DRUG DISCOVERY; HUMANS; MOLECULAR CHAPERONES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; PARKINSON DISEASE;

EID: 84906678530     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413111111     Document Type: Note

References (13)

1. Geschwind DH, Konopka G (2009) Neuroscience in the era of functional genomics and systems biology. Nature 461(7266):908-915.
2. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1(9):727-730. (Pubitemid 37361545)
3. Kay MA (2011) State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet 12(5):316-328.
4. Groll M, Huber R, Moroder L (2009) The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 15(2):58-66.
5. Ringe D, Petsko GA (2009) What are pharmacological chaperones and why are they interesting? J Biol 8(9):80.
6. Pavlopoulos E, et al. (2013) Molecular mechanism for age-related memory loss: The histone-binding protein RbAp48. Sci Transl Med 5(200):200ra115.
7. Small SA, et al. (2005) Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol 58(6):909-919. (Pubitemid 41746881)
8. Oh M, et al. (2014) Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein. Proc Natl Acad Sci USA 111(30):11007-11012.
9. Morello JP, Petäjä-Repo UE, Bichet DG, Bouvier M (2000) Pharmacological chaperones: A new twist on receptor folding. Trends Pharmacol Sci 21(12):466-469.
10. Mattos C, Ringe D (1996) Locating and characterizing binding sites on proteins. Nat Biotechnol 14(5):595-599. (Pubitemid 26135122)
11. Henrich S, et al. (2010) Computational approaches to identifying and characterizing protein binding sites for ligand design. J Mol Recognit 23(2):209-219.
12. Lieberman RL, et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3(2):101-107. (Pubitemid 46134996)
13. Mecozzi VJ, et al. (2014) Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol 10(6):443-449.